Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., Schilling, B., Schummer, P., Sirokay, J., Kiecker, F., Owen, C. N., Fleischer, M. I., Cann, C., Kähler, K. C., Mohr, P., Bluhm, L., Niebel, D., Thoms, K., Goldinger, S. M., Reinhardt, L., Meier, F., Berking, C., Reinhard, R., Susok, L., Ascierto, P. A., Drexler, K., Pföhler, C., Tietze, J., Heinzerling, L., Livingstone, E., Ugurel, S., Long, G. V., Stang, A., Schadendorf, D., & Zimmer, L. (2021). outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European journal of cancer, 148, 61–75. http://access.bl.uk/ark:/81055/vdc_100129510392.0x000025